Evidence map›Paper›PMID 42557374›Full record

ArticleCell death and differentiation2026

The kinase CK1α coordinates the initiation and termination of the cGAS-STING pathway.

Jane Jardine, Marine Tarrillon, Gwennan André-Grégoire, Kilian Trillet, Vanessa Josso, Laura Merlet, Rosalie Moreau, Célia Jaunasse, Luc Antigny, Séverine Marionneau-Lambot and 9 more

Abstract read
PubMed Publisher
In one paragraph

Article in Cell death and differentiation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jane JardineCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Marine TarrillonCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Gwennan André-GrégoireCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Kilian TrilletCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Vanessa JossoCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Laura MerletCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Rosalie MoreauCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Célia JaunasseCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Luc AntignyCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Séverine Marionneau-LambotCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
François GuillonneauCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Alice BoissardProt'ICO, Institut de Cancérologie de l'Ouest, Angers, France.
Cécile HenryProt'ICO, Institut de Cancérologie de l'Ouest, Angers, France.
Joanna ReInstitut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier, CNRS UMR5535, Montpellier, France.
Sophie Barillé-NionCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.ORCID http://orcid.org/0000-0001-5171-9937
Nadine LaguetteInstitut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier, CNRS UMR5535, Montpellier, France.
Philippe P JuinCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.
Julie GavardCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France.ORCID http://orcid.org/0000-0002-7985-9007
Nicolas BidèreCRCI2NA, Nantes Université, INSERM, CNRS, Université d'Angers, Nantes, France. nicolas.bidere@inserm.fr.ORCID http://orcid.org/0000-0001-9177-0008

Funding

EC | EU Framework Programme for Research and Innovation H2020 | H2020 Priority Excellent Science | H2020 European Research Council (H2020 Excellent Science - European Research Council) SENTINEL 101087092
6 · The paper itself

Abstract

The cGAS-STING pathway is an evolutionarily conserved DNA-sensing mechanism that triggers innate immune responses. cGAS and STING play dual roles in tumorigenesis, promoting antitumor immunity and cell death while fueling tumor growth and metastasis. However, the mechanisms fine-tuning this pathway remain elusive. Using complementary proteomic approaches, we report that Casein Kinase 1 alpha (CK1α) operates as a bimodal regulator of the cGAS-STING pathway. CK1α supports optimal DNA sensing by counteracting proteasome-dependent degradation of cGAS, which involves the Cullin-RING ubiquitin ligase 3 (CRL3). Conversely, CK1α restrains signal propagation in response to STING agonists, tempering IRF3 activation. Exploiting these counterposing functions, we show that selective degradation of CK1α using molecular-glue degraders suppressed aberrant cGAS-STING-driven inflammation signaling in a chromosomally unstable triple-negative breast cancer cell line, while cooperating with a STING agonist to promote apoptosis in acute myeloid leukemia cells. Thus, CK1α's dual regulatory role in the cGAS-STING pathway presents a promising target for therapeutic development.

Identifiers

PMID42557374

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.